Alkermes plc buy melinda
Start price
19.06.17
/
50%
€57.15
Target price
05.07.17
€60.00
Performance (%)
5.28%
End price
05.07.17
€60.17
Summary
This prediction ended on 05.07.17 with a price of €60.17. With a performance of 5.28%, the BUY prediction by melinda for Alkermes plc closed with a slight gain. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alkermes plc | -3.597% | -3.597% | -19.760% | 3.555% |
| iShares Core DAX® | 1,43 % | 1,58 % | 13,25 % | 61,14 % |
| iShares Nasdaq 100 | 1,89 % | -2,28 % | 2,99 % | 88,34 % |
| iShares Nikkei 225® | -1,62 % | 7,95 % | 27,69 % | 65,18 % |
| iShares S&P 500 | 1,92 % | -0,28 % | 2,99 % | 61,15 % |
Comments by melinda for this prediction
In the thread Alkermes plc diskutieren
Die US Food and Drug Administration (FDA) genehmigt hat ALKERMES des zweimonatigen Aristada (Aripiprazol lauroxil) extended-release injizierbare Suspension zur Behandlung von Schizophrenie.